This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.
General Information
Mice: C57BL/6
The human LRRK2 protein is expressed under the control of a mini version of the neuronal specific promoter Thy1.2.
Endogenous LRRK2: yes
Corresponding human genotype: LRRK2 is a major known genetic contributor to Parkinson’s disease.
Targeted gene: LRRK2
References: Garcia-Miralles 2015
Transgene expression
- 4 and 11 months: The total level of LRRK2 protein is 2 times higher than the level measured in the brain of non-transgenic animals. Expression is found at high level in the cortex and hippocampus but no expression of the human LRRK2 protein is detected in the SN.
Neurodegeneration
- 12-13 months: No obvious neurodegeneration is observed in the SN.
Dopamine Homeostasis
- Not reported
Inclusions
- 11 months: No differences in the levels of alpha-synuclein are observed in the brain of transgenic animals.
Motor Behaviours
- Not reported
Response to dopaminergic treatment
- Not reported
Non-motor Behaviours
- Not reported
Electrophysiology
- Not reported
Neuroinflammation
- Not reported